Investor Ally Bridge MedAlpha Master Fund L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Ally Bridge MedAlpha Master Fund L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-02-13 13G/A SYRS / Syros Pharmaceuticals, Inc. 1,439,379 570,976
2023-01-30 13G/A SYRS / Syros Pharmaceuticals, Inc. 1,439,379 1,439,379
2022-02-11 13G/A VRDN / Viridian Therapeutics, Inc. 929,979 604,774
2022-02-11 13G/A COGT / Cogent Biosciences, Inc. 1,622,591 1,501,591
2022-02-11 13G/A SYRS / Syros Pharmaceuticals, Inc. 3,033,125 3,930,520
2021-02-12 13G/A COGT / Cogent Biosciences, Inc. 1,622,591
2021-01-07 13G VRDN / Viridian Therapeutics, Inc. 929,979
2021-01-07 13G VRDN / Viridian Therapeutics, Inc. 929,979
2020-12-18 13G SYRS / Syros Pharmaceuticals, Inc. 3,033,125